{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T13:25:36Z","timestamp":1782998736397,"version":"3.54.5"},"reference-count":65,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008207","name":"AstraZeneca Canada Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008207","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cjcopen.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.cjco.2025.03.002","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T17:19:07Z","timestamp":1741627147000},"page":"614-627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Diagnosis and Management of Mixed Phenotype Hereditary Transthyretin Amyloidosis: A Case-Based, Canadian Perspective"],"prefix":"10.1016","volume":"7","author":[{"given":"Nowell","family":"Fine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anique","family":"Ducharme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Matte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Mezei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Bril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2025.03.002_bib1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THAOS\u2014The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis","volume":"29","author":"Coelho","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cjco.2025.03.002_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40119-023-00344-3","article-title":"Clinical and genotype characteristics and symptom migration in patients with mixed phenotype transthyretin amyloidosis from the Transthyretin Amyloidosis Outcomes Survey","volume":"13","author":"Gonz\u00e1lez-Moreno","year":"2024","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.cjco.2025.03.002_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cjco.2025.03.002_bib4","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s13023-023-02962-5","article-title":"A\u00a015-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"18","author":"Gentile","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cjco.2025.03.002_bib5","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/mus.26034","article-title":"Estimating the global prevalence of transthyretin familial amyloid polyneuropathy","volume":"57","author":"Schmidt","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.cjco.2025.03.002_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1017\/cjn.2021.34","article-title":"Canadian guidelines for hereditary transthyretin amyloidosis polyneuropathy management","volume":"49","author":"Alcantara","year":"2022","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.cjco.2025.03.002_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14797\/mdcvj.1066","article-title":"ATTR epidemiology, genetics, and prognostic factors","volume":"18","author":"Obi","year":"2022","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"Suppl 1","key":"10.1016\/j.cjco.2025.03.002_bib8","doi-asserted-by":"crossref","first-page":"P22","DOI":"10.1186\/1750-1172-10-S1-P22","article-title":"Patient experience with hereditary and senile systemic amyloidoses: a survey from the Amyloidosis Research Consortium","volume":"10","author":"Lousada","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cjco.2025.03.002_bib9","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.cjco.2025.03.002_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10741-024-10444-4","article-title":"Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis","volume":"30","author":"Girard","year":"2025","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cjco.2025.03.002_bib11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.cjca.2019.12.034","article-title":"Canadian Cardiovascular Society\/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosis","volume":"36","author":"Fine","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2025.03.002_bib12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12875-020-01252-4","article-title":"Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner","volume":"21","author":"Gertz","year":"2020","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.cjco.2025.03.002_bib13","first-page":"2109","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"Adams","year":"2021","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.cjco.2025.03.002_bib14","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjco.2025.03.002_bib15","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2025.03.002_bib16","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2025.03.002_bib17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mus.28026","article-title":"Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: recommendations from a panel of experts","volume":"69","author":"Karam","year":"2024","journal-title":"Muscle Nerve"},{"issue":"Suppl 1","key":"10.1016\/j.cjco.2025.03.002_bib18","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/WCO.0000000000000290","article-title":"Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis","volume":"29","author":"Obici","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.cjco.2025.03.002_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241250208","article-title":"Enhanced MRI radiomics based model for predicting recurrence or metastasis of nasopharyngeal cancer (NC) undergoing concurrent chemoradiotherapy: a retrospective study","volume":"31","author":"Song","year":"2024","journal-title":"Cancer Control"},{"key":"10.1016\/j.cjco.2025.03.002_bib20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis","volume":"68","author":"Maurer","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2025.03.002_bib21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40119-021-00226-6","article-title":"Phenotypic differences of Glu89Gln genotype in ATTR amyloidosis from endemic loci: update from THAOS","volume":"10","author":"Gentile","year":"2021","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.cjco.2025.03.002_bib22","first-page":"5746","article-title":"Hereditary transthyretin amyloidosis: a myriad of factors that influence phenotypic variability","volume":"271","author":"Carvalho","year":"2024","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.cjco.2025.03.002_bib23","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/13506129.2022.2046557","article-title":"Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays","volume":"29","author":"Kaku","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.cjco.2025.03.002_bib24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/jns.12385","article-title":"Description of a large cohort of Caucasian patients with V122I ATTRv amyloidosis: neurological and cardiological features","volume":"25","author":"Gentile","year":"2020","journal-title":"J\u00a0Peripher Nerv Syst"},{"key":"10.1016\/j.cjco.2025.03.002_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91113-6","article-title":"Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry","volume":"11","author":"Parker","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.cjco.2025.03.002_bib26","doi-asserted-by":"crossref","first-page":"e2036","DOI":"10.1212\/WNL.0000000000207158","article-title":"Phenotypes associated with the Val122Ile, Leu58His, and late-onset Val30Met variants in patients with hereditary transthyretin amyloidosis","volume":"100","author":"Zampino","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.cjco.2025.03.002_bib27","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1212\/WNL.0000000000004016","article-title":"Early skin denervation in hereditary and iatrogenic transthyretin amyloid neuropathy","volume":"88","author":"Masuda","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.cjco.2025.03.002_bib28","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ana.25433","article-title":"Skin nerve pathology: biomarkers of premanifest and manifest amyloid neuropathy","volume":"85","author":"Chao","year":"2019","journal-title":"Ann Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.cjco.2025.03.002_bib29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10286-019-00623-x","article-title":"Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management","volume":"29","author":"Palma","year":"2019","journal-title":"Clin Auton Res"},{"key":"10.1016\/j.cjco.2025.03.002_bib30","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jcmg.2016.06.003","article-title":"Can (99m)Tc-pyrophosphate aid in early detection of cardiac involvement in asymptomatic variant TTR amyloidosis?","volume":"10","author":"Haq","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjco.2025.03.002_bib31","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/ene.14285","article-title":"Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial","volume":"27","author":"Brannagan","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.cjco.2025.03.002_bib32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","article-title":"Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study","volume":"20","author":"Adams","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cjco.2025.03.002_bib33","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2025.03.002_bib34","first-page":"2802","article-title":"Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"Coelho","year":"2013","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.cjco.2025.03.002_bib35","first-page":"268","article-title":"Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study","volume":"264","author":"Plant\u00e9-Bordeneuve","year":"2017","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.cjco.2025.03.002_bib36","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2025.03.002_bib37","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2025.03.002_bib38","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","article-title":"Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis","volume":"26","author":"Lohrmann","year":"2020","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.cjco.2025.03.002_bib39","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/13506129.2018.1519507","article-title":"Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center\u2019s experience","volume":"25","author":"Ikram","year":"2018","journal-title":"Amyloid"},{"issue":"Suppl 1","key":"10.1016\/j.cjco.2025.03.002_bib40","doi-asserted-by":"crossref","first-page":"O23","DOI":"10.1186\/1750-1172-10-S1-O23","article-title":"Diflunisal therapy for cardiac ATTR amyloidosis: a longitudinal, prospective, single centre study","volume":"10","author":"Quarta","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cjco.2025.03.002_bib41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2025.03.002_bib42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2025.03.002_bib43","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2025.03.002_bib44","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.cjco.2025.03.002_bib45","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2025.03.002_bib46","first-page":"31","article-title":"HELIOS-A: 18-month exploratory cardiac results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis","volume":"15","author":"Garcia Pavia","year":"2023","journal-title":"Arch Cardiovasc Dis Suppl"},{"key":"10.1016\/j.cjco.2025.03.002_bib47","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2023.11.016","article-title":"Effect of eplontersen on cardiac structure and function in patients with hereditary transthyretin amyloidosis","volume":"30","author":"Masri","year":"2024","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.cjco.2025.03.002_bib48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2025.03.002_bib49","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in\u00a0vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2025.03.002_bib50","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2025.03.002_bib51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","article-title":"Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations","volume":"26","author":"Concei\u00e7\u00e3o","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.cjco.2025.03.002_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2024.101948","article-title":"Rationale & design of ACT-EARLY, the acoramidis transthyretin amyloidosis prevention trial: early detection using cardiac radionuclide imaging","volume":"38","author":"Soman","year":"2024","journal-title":"J\u00a0Nucl Cardiol"},{"key":"10.1016\/j.cjco.2025.03.002_bib53","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjco.2025.03.002_bib54","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s13023-021-01960-9","article-title":"Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression","volume":"16","author":"Adams","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cjco.2025.03.002_bib55","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jacc.2023.12.036","article-title":"Stratifying disease progression in patients with cardiac ATTR amyloidosis","volume":"83","author":"Ioannou","year":"2024","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"Pt 3","key":"10.1016\/j.cjco.2025.03.002_bib56","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/brain\/awu344","article-title":"In\u00a0vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography","volume":"138","author":"Kollmer","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.cjco.2025.03.002_bib57","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1212\/WNL.0000000000004178","article-title":"Sural nerve injury in familial amyloid polyneuropathy: MR neurography vs clinicopathologic tools","volume":"89","author":"Kollmer","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.cjco.2025.03.002_bib58","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/mus.24168","article-title":"Ultrasound evaluation in transthyretin-related amyloid neuropathy","volume":"50","author":"Granata","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.cjco.2025.03.002_bib59","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.clinph.2017.01.013","article-title":"Peripheral nerve ultrasonography in patients with transthyretin amyloidosis","volume":"128","author":"Podnar","year":"2017","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.cjco.2025.03.002_bib60","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mus.21332","article-title":"Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy","volume":"40","author":"Kim","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.cjco.2025.03.002_bib61","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000251","article-title":"Axon reflex-mediated vasodilation is reduced in proportion to disease severity in TTR-FAP","volume":"4","author":"Calero-Romero","year":"2018","journal-title":"Neurol Genet"},{"key":"10.1016\/j.cjco.2025.03.002_bib62","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.clinph.2008.01.006","article-title":"Neurophysiological markers in familial amyloid polyneuropathy patients: early changes","volume":"119","author":"Concei\u00e7\u00e3o","year":"2008","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.cjco.2025.03.002_bib63","first-page":"1497","article-title":"Neurophysiological markers of small fibre neuropathy in TTR-FAP mutation carriers","volume":"260","author":"Lefaucheur","year":"2013","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.cjco.2025.03.002_bib64","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.clinph.2016.02.013","article-title":"The diagnostic accuracy of sudoscan in transthyretin familial amyloid polyneuropathy","volume":"127","author":"Castro","year":"2016","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.cjco.2025.03.002_bib65","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1001\/jamaophthalmol.2016.1889","article-title":"Potential role of in\u00a0vivo confocal microscopy for imaging corneal nerves in transthyretin familial amyloid polyneuropathy","volume":"134","author":"Rousseau","year":"2016","journal-title":"JAMA Ophthalmol"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X25001180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X25001180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T01:34:00Z","timestamp":1747100040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X25001180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2589790X25001180"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2025.03.002","relation":{},"ISSN":["2589-790X"],"issn-type":[{"value":"2589-790X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and Management of Mixed Phenotype Hereditary Transthyretin Amyloidosis: A Case-Based, Canadian Perspective","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2025.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}